GlassScriptPhysician profile
Ethan D Schram
NPI 1659320703
$10,594.06
in general payments reported to CMS, 2019-2025
51 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,591 · 2020: $231 · 2021: $552 · 2022: $571 · 2023: $627 · 2024: $4,639 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782 · Consulting Fee: $1,650 · Honoraria: $1,100 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,782.33 |
| Consulting Fee | $1,650.00 |
| Honoraria | $1,100.00 |
| Education | $116.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $3,160.35 | 2022-2025 | Myrisk, Precisetumor |
| Janssen Biotech, INC. | $1,616.08 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Astrazeneca Pharmaceuticals LP | $708.71 | 2021-2025 | Enhertu, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $538.15 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $508.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $331.50 | 2022-2025 | |
| Daiichi Sankyo INC. | $246.91 | 2024-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $244.76 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Celgene Corporation | $214.70 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Genentech USA, INC. | $210.09 | 2023-2025 | Phesgo, Polivy, Itovebi |
| Abbvie INC. | $198.38 | 2022-2025 | |
| Ge Healthcare | $180.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $174.09 | 2024-2025 | Opdivo, Opdualag |
| Incyte Corporation | $173.91 | 2019-2025 | Jakafi |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $123.73 | 2021 | |
| Array Biopharma INC | $123.61 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Glaxosmithkline, LLC. | $119.72 | 2024-2025 | Zejula, Jemperli |
| Amag Pharmaceuticals, INC. | $103.08 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $101.95 | 2024-2025 | Libtayo |
| Intuitive Surgical, INC. | $98.10 | 2024 | |
| Ethicon INC. | $97.76 | 2022 | |
| Genzyme Corporation | $93.15 | 2023 | |
| Amgen INC. | $88.53 | 2021-2022 | |
| Medtronic, INC. | $73.32 | 2022 | |
| Seagen INC. | $68.48 | 2020-2023 | Tukysa |
| Syndax Pharmaceuticals, INC. | $60.47 | 2025 | |
| Karyopharm Therapeutics INC. | $60.42 | 2024-2025 | Xpovio |
| Lilly USA, LLC | $51.07 | 2021-2025 | Verzenio |
| Progenics Pharmaceuticals, INC. | $49.92 | 2022-2024 | |
| Teleflex LLC | $48.37 | 2019-2021 | |
| Eisai INC. | $47.01 | 2024-2025 | |
| Blue Earth Diagnostics | $45.88 | 2019 | |
| Acrotech Biopharma INC. | $39.83 | 2022 | |
| Geron Corporation | $39.06 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $34.10 | 2025 | Onivyde |
| Taiho Oncology, INC. | $31.59 | 2025 | |
| Foundation Medicine, INC. | $28.90 | 2019 | |
| Kyowa Kirin, INC. | $27.36 | 2023 | Poteligeo |
| Beone Medicines USA, INC. | $25.48 | 2025 | Tevimbra |
| Myovant Sciences INC. | $25.42 | 2021 | |
| Beigene USA, INC. | $23.79 | 2025 | Brukinsa |
| Novocure INC. | $23.32 | 2025 | Optune Lua (Novottf-200t) |
| Invivyd INC | $22.42 | 2025 | Pemgarda |
| Mirati Therapeutics, INC. | $22.40 | 2024 | Krazati |
| Tersera Therapeutics LLC | $22.12 | 2025 | Zoladex |
| Tactile Systems Technology INC | $18.97 | 2025 | Nimbl, Flexitouch Plus |
| Tesaro, INC. | $18.41 | 2019 | |
| Caris Mpi, INC. | $17.68 | 2025 | Mi Cancer Seek |
| Siemens Medical Solutions USA, INC. | $16.75 | 2023 | Aria Radiation Therapy Management Software |
| Bard Peripheral Vascular, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Schram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.